SubscribeLoginCustomer Service


ADVANCED SEARCH
Log In
Home
Blog
Free Samples
Conferences
Research
Databank
Current Issue
Archives
READER'S CHOICE
Most Popular Stories
Purvis Industries Buys Bearing Belt Chain
One Distributor's Experience in Greening Its Warehouse
Latin America Manufacturing Production Growth to Slow
Owens & Minor to Sell Direct-to-Consumer Diabetes Business
The Year in Distribution: 2008
HOME
ABOUT MDM
CONTACT US
CUSTOMER SERVICE
Copyright © 2009
Gale Media, Inc.
All Rights Reserved.
E-Mail This Article
Printer-Friendly Version
Related Articles from MDM

Microsoft
Untitled Document

Enter your email address below to receive our FREE weekly email, MDM Advisor, with industry news, trends and analysis for wholesale distribution executives.

November 21, 2008

McKesson Agrees to Settle Pricing Case for $350M

By MDM Staff

McKesson Corp., San Francisco, CA, has reached an agreement to settle damage claims  of inflated prices on prescription drugs paid by private health-benefit plans and individuals. The company has agreed to pay $350 million. With the settlement, the drug distributor continues to deny the claims made in the lawsuit.
 
The terms are subject to final court approval.
 
The company will also record a reserve for outstanding and expected future claims by public entities, which is estimated to be $143 million.
 
“As we have consistently stated, we believe the plaintiffs’ allegations are without merit, and that McKesson adhered to all applicable laws,” said John H. Hammergren, CEO. “Yet when faced with the inherent uncertainty of this litigation, we determined that entering into the settlement agreement was in the best interest of our shareholders, customers, suppliers and employees.”
 
McKesson has more than $100 billion in annual revenues.
 
The lawsuit alleged that McKesson – one of the largest pharmaceutical distributors in North America – entered into a secret agreement to artificially inflate the reported average wholesale price of thousands of drugs, a benchmark used by Medicaid and insurance plans to determine payment to pharmacies.
According to the complaint, beginning in late 2001, McKesson and First Databank, a publishing company, reached an agreement on how the AWP would be set for brand-name drugs, and in doing so, raised the spread between the published AWP and the actual acquisition costs in an effort to increase profits.
 
First Databank has already reached a settlement with the plaintiffs including a rollback of AWP prices and an agreement to stop publishing the data.

More Breaking News


  • Pelican Advanced Area Lighting, Lighting Technology of Another Kind
  • Microsoft Dynamics® Case Study: A Platform for Aggressive Growth
  • Infor's Distribution Success Stories: Secrets from Enterprising Distributors
  • Benchmark Your Inventory Management
  • Click here to download this IBM Executive Information Kit
  • HOME PRIVACY COPYRIGHT SUBSCRIBE

    GALE MEDIA OUR PRODUCTS ADVERTISING